Iselin, New Jersey - On December 19, 2025, Outlook Therapeutics, Inc. disclosed their financial report for the fiscal year 2025. The biopharmaceutical company, listed as Nasdaq: OTLK, concentrates on improving the treatment standard of bevacizumab for retina diseases.